Ginsenoside Rh1 protects human endothelial cells against lipopolysaccharide-induced inflammatory injury through inhibiting TLR2/ 4-mediated STAT3, NF-?B, and ER stress signaling pathways

被引:18
|
作者
Jin, Yujin [1 ,2 ]
Nguyen, Thuy Le Lam [1 ,2 ]
Myung, Chang-Seon [1 ,2 ]
Heo, Kyung-Sun [1 ,2 ,3 ,4 ]
机构
[1] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
[2] Chungnam Natl Univ, Inst Drug Res & Dev, Daejeon 34134, South Korea
[3] Chungnam Natl Univ, Coll Pharm, 99 Daehak Ro, Daejeon, South Korea
[4] Chungnam Natl Univ, Inst Drug Res & Dev, 99 Daehak Ro, Daejeon, South Korea
关键词
Ginsenoside Rh1; Endothelial cell dysfunction; Lipopolysaccharide; ER stress; STAT3; NF-?B; Human umbilical vein endothelial cells; ENDOPLASMIC-RETICULUM STRESS; BREAST-CANCER CELLS; MAPK; ATHEROSCLEROSIS; APOPTOSIS; ROS;
D O I
10.1016/j.lfs.2022.120973
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aim: Endothelial cell (EC) dysfunction initiates atherosclerosis by inducing inflammatory cytokines and adhesion molecules. Herein, we investigated the role of ginsenoside Rh1 (Rh1) in lipopolysaccharide (LPS)-induced EC dysfunction.Main methods: The inhibitory effect of Rh1 on LPS binding to toll-like receptor 2 (TLR2) or TLR4 was evaluated using an immunofluorescence (IF) assay. Annexin V and cleaved caspase-3-positive EC apoptosis were evaluated by flow cytometry and IF assay. Western blotting and quantitative reverse transcription-PCR were performed to clarify underlying molecular mechanisms. In vivo model, effect of Rh1 on EC dysfunction was evaluated by using en face IF assay on aortas isolated C57BL/6 mice. Key finding: LPS (500 ng/mL) activated inflammatory signaling pathways, including ERK1/2, STAT3, and NF-kappa B. Interestingly, Rh1 significantly abolished the binding of LPS to TLR2 and TLR4. Consistently, Rh1 inhibited LPS-induced NF-kappa B activation and its downstream molecules, including inflammatory cytokines and adhesion mol-ecules. Furthermore, Rh1 alleviated LPS-induced downregulation of eNOS promoter activity. Notably, inacti-vation of eNOS by 50 mu M L-NAME significantly increased NF-& UKappa;B promoter activity. In addition, Rh1 abolished LPS-mediated cell cycle arrest and EC apoptosis by inhibiting endoplasmic reticulum stress via PERK/CHOP/ ERO1-alpha signaling pathway. Consistent with in vitro experimental data, Rh1 effectively suppressed LPS-induced VCAM-1 and CHOP expression and rescuing LPS-destroyed tight junctions between ECs as indicated in ZO-1 expression on mice aorta. Significance: Rh1 suppresses LPS-induced EC inflammation and apoptosis by inhibiting STAT3/NF-& UKappa;B and endoplasmic reticulum stress signaling pathways, mediated by blocking LPS binding-to TLR2 and TLR4. Consistently, Rh1 effectively reduced EC dysfunction in vivo model.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Protective role of ginsenoside Rh1 on LPS-induced endothelial cell injury through suppressing TLR2/4-mediated STAT3, NF-κB and ER stress signaling pathway
    Jin, Yujin
    Nguyen, Thuy Le Lam
    Heo, Kyung-sun
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 718 - 720
  • [2] Astaxanthin protects lipopolysaccharide-induced inflammatory response in Channa argus through inhibiting NF-κB and MAPKs signaling pathways
    Li, Mu-Yang
    Sun, Li
    Niu, Xiao-Tian
    Chen, Xiu-Mei
    Tian, Jia-Xin
    Kong, Yi-Di
    Wang, Gui-Qin
    FISH & SHELLFISH IMMUNOLOGY, 2019, 86 : 280 - 286
  • [3] Deoxyelephantopin alleviates lipopolysaccharide-induced septic lung injury through inhibiting NF-κB/STAT3 axis
    Wang, Shu
    Chen, Yuefeng
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2022, 50 (05) : 39 - 46
  • [4] Ampelopsin attenuates lipopolysaccharide-induced inflammatory response through the inhibition of the NF-κB and JAK2/STAT3 signaling pathways in microglia
    Weng, Leihua
    Zhang, He
    Li, Xiaoxi
    Zhan, Hui
    Chen, Fan
    Han, Lijuan
    Xu, Yun
    Cao, Xiang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 44 : 1 - 8
  • [5] Artemisinin Protects Porcine Mammary Epithelial Cells against Lipopolysaccharide-Induced Inflammatory Injury by Regulating the NF-κB and MAPK Signaling Pathways
    Zhang, Wenfei
    Xiong, Liang
    Chen, Jiaming
    Tian, Zhezhe
    Liu, Jiaxin
    Chen, Fang
    Ren, Man
    Guan, Wutai
    Zhang, Shihai
    ANIMALS, 2021, 11 (06):
  • [6] Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-κB and STAT3 Pathways in RAW 264.7 Cells and Zebrafish
    Chun-hong Zhou
    Hua Yang
    Li-fang Zou
    Di-fa Liu
    Lin-zhong Yu
    Hui-hui Cao
    Li-e Deng
    Zhang-wei Wang
    Zi-bin Lu
    Jun-shan Liu
    Chinese Journal of Integrative Medicine, 2023, 29 : 1111 - 1120
  • [7] Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-κB and STAT3 Pathways in RAW 264.7 Cells and Zebrafish
    ZHOU Chunhong
    YANG Hua
    ZOU Lifang
    LIU Difa
    YU Linzhong
    CAO Huihui
    DENG Lie
    WANG Zhangwei
    LU Zibin
    LIU Junshan
    Chinese Journal of Integrative Medicine, 2023, 29 (12) : 1111 - 1120
  • [8] Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-κB and STAT3 Pathways in RAW 264.7 Cells and Zebrafish
    ZHOU Chun-hong
    YANG Hua
    ZOU Li-fang
    LIU Di-fa
    YU Lin-zhong
    CAO Hui-hui
    DENG Li-e
    WANG Zhang-wei
    LU Zi-bin
    LIU Jun-shan
    Chinese Journal of Integrative Medicine, 2023, (12) : 1111 - 1120
  • [9] Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-κB and STAT3 Pathways in RAW 264.7 Cells and Zebrafish
    Zhou Chun-hong
    Yang Hua
    Zou Li-fang
    Liu Di-fa
    Yu Lin-zhong
    Cao Hui-hui
    Deng Li-e
    Wang Zhang-wei
    Lu Zi-bin
    Liu Jun-shan
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2023, 29 (12) : 1111 - 1120
  • [10] Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-?B and STAT3 Pathways in RAW 264.7 Cells and Zebrafish
    Zhou, Chun-hong
    Yang, Hua
    Zou, Li-fang
    Liu, Di-fa
    Yu, Lin-zhong
    Cao, Hui-hui
    Deng, Li-e
    Wang, Zhang-wei
    Lu, Zi-bin
    Liu, Jun-shan
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2023,